Neuropace is a medical device company focused on transforming the lives of people with epilepsy. Co.'s RNS System is a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By monitoring the brain's electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, Co.'s RNS System is programmed by clinicians to deliver the amount of therapy when and where it is needed and provides exceptional clinical outcomes. Co.'s RNS System records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The NPCE average annual return since 2021 is shown above.
The Average Annual Return on the NPCE average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NPCE average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NPCE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|